目次

Table of Content

1. Introduction to Peptide Drugs
1.1 History, Development and Evolution
1.2 Approved Peptide Drugs

2. Peptide Drugs - Therapeutic, Diagnostic and Theranostic Potential and Market Implications
2.1 Therapeutic Potential and Market Implications
2.2 Diagnostic Potential and Market Implications
2.3 Theranostic Potential and Market Implications

3. Global Peptide Drugs Clinical Research and Market Trends by Indication
3.1 Inheritable Genetic Diseases
3.2 Cancer
3.3 Microbial Infections
3.4 Autoimmune Disorders
3.5 Metabolic Disorders
3.6 Neurodegenerative Diseases

4. Peptide Based Therapeutic Approaches
4.1 Peptide Hormone Drugs
4.2 Peptide Drug Conjugates
4.3 Peptide Vaccines
4.4 Peptide Agonists
4.5 Peptide Aptamers
4.6 Peptide Antibody

5. Global Peptide Therapeutics Market Outlook
5.1 Current Market Trends and Drivers
5.2 Future Growth Avenues

6. Peptide Therapeutics Market Landscape by Region
6.1 US
6.2 EU
6.3 China
6.4 Japan
6.5 South Korea
6.6 UK
6.7 India
6.8 Middle East
6.9 Canada
6.10 Australia

7. Global Peptide Therapeutics Clinical Trials Overview
7.1 By Country
7.2 Indication
7.3 Phase
7.4 Priority Status
7.5 Therapy Class

8. Marketed Peptide Drugs Insight - Patent, Availability, Cost, Dosage, and Sales Insight

8.1 Bylvay
8.1.1 Overview
8.1.2 Pricing and Dosage Analysis
8.1.3 Sales Insight

8.2 Parsabiv
8.2.1 Overview and PatentS Insight
8.2.2 Pricing and Dosage Analysis
8.2.3 Sales Insight

8.3 Bydureon BCise
8.3.1 Overview and Patent Insight
8.3.2 Pricing and Dosage Analysis
8.3.3 Sales Insight

8.4 Linzess
8.4.1 Overview and Patent Insight
8.4.2 Pricing and Dosage Insight
8.4.3 Sales Insight

8.5 Increlex
8.5.1 Overview and Patent Insight
8.5.2 Pricing and Dosage Insight
8.5.3 Sales Analysis

8.6 Terlivaz
8.6.1 Overview and Patent Insight
8.6.2 Pricing and Dosage Insight
8.6.3 Sales Analysis

8.7 Empaveli
8.7.1 Overview and Patent Insight
8.7.2 Pricing and Dosage Insight
8.7.3 Sales Analysis

8.8 Voxzogo
8.8.1 Overview and Patent Insight
8.8.2 Pricing and Dosage Insight
8.8.3 Sales Analysis

8.9 Imcivree
8.9.1 Overview and Patent Insight
8.9.2 Pricing and Dosage Insight
8.9.3 Sales Analysis

8.10 Trulicity
8.10.1 Overview and Patent Insight
8.10.2 Pricing and Dosage Insight
8.10.3 Sales Analysis

8.11 Ozempic
8.11.1 Overview and Patent Insight
8.11.2 Pricing and Dosage Insight
8.11.3 Sales Analysis

8.12 Wegovy
8.12.1 Overview and Patent Insight
8.12.2 Pricing and Dosage Insight
8.12.3 Sales Analysis

8.13 Tresiba
8.13.1 Overview and Patent Insight
8.13.2 Pricing and Dosage Insight
8.13.3 Sales Analysis

8.14 Rybelsus
8.14.1 Overview and Patent Insight
8.14.2 Pricing and Dosage Insight
8.14.3 Sales Analysis

8.15 Xultophy
8.15.1 Overview and Patent Insight
8.15.2 Pricing and Dosage Insight
8.15.3 Sales Analysis

8.16 Victoza
8.16.1 Overview and Patent Insight
8.16.2 Pricing and Dosage Insight
8.16.3 Sales Analysis

8.17 Ryzodeg
8.17.1 Overview and Patent Insight
8.17.2 Pricing and Dosage Insight
8.17.3 Sales Analysis

8.18 Fiasp
8.18.1 Overview and Patent Insight
8.18.2 Pricing and Dosage Insight
8.18.3 Sales Analysis

8.19 Lantus
8.19.1 Overview and Patent Insight
8.19.2 Pricing and Dosage Insight
8.19.3 Sales Analysis

8.20 Toujeo
8.20.1 Overview and Patent Insight
8.20.2 Pricing and Dosage Insight
8.20.3 Sales Analysis

9. Peptide Therapeutics Development Technologies Platform
9.1 Biodrug Design Accelerator - Fujitsu/PeptiDream
9.2 T-Winandreg; Technology - IO Biotech
9.3 Numatech - Numaferm
9.4 ProteinStudio - ProteinQure
9.5 The Magnifier Nandpi;andPhi;andtrade; - Nuritas
9.6 PepPower - GenScript
9.7 Unnamed Peptide Platform - Zealand Pharma
9.8 PDPS (Peptide Discovery Platform System) - PeptiDream
9.9 Veneno Suite - Veneno Technologies
9.10 SmartDepotandtrade; Technology - Peptron
9.11 Bicycles - Bicycle Therapeutics
9.12 RALA Technolgy - pHion Therapeutics
9.13 Discovery Platform - Orbit Discovery
9.14 Imotopes - Imcyse
9.15 Nautilus - Peptilogics
9.16 Swarm Intelligence 2.0 - Pepticom
9.17 streaMLine Platform - Gubra
9.18 Precision Endocrine Peptides (PEPs) - MBX Biosciences
9.19 pHLIP (pH-Low Insertion Peptides) - pHLIP
9.20 alphalex - Cybrexa

10. Cyclic Peptides Clinical Trials Insight By Country, Indication and Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-II/III
10.7 Phase-III
10.8 Preregistration
10.9 Registered
10.10 Marketed

11. Peptide Hormones Clinical Trials Insight By Country, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-II/III
11.7 Phase-III
11.8 Preregistration
11.9 Registered
11.10 Marketed

12. Peptides Clinical Trials Insight By Country, Indication and Phase
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-II/III
12.7 Phase-III
12.8 Preregistration
12.9 Registered
12.10 Marketed

13. Glucagon-Like Peptides Clinical Trials Insight By Country, Indication and Phase
13.1 Preclinical
13.2 Phase-I
13.3 Phase-I/II
13.4 Phase-II
13.5 Phase-III
13.6 Marketed

14. Oligopeptides Clinical Trials Insight By Country, Indication and Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-II/III
14.7 Phase-III
14.8 Registered
14.9 Marketed

15. Lipopeptides Clinical Trials Insight By Country, Indication and Phase
15.1 Research
15.2 Preclinical
15.3 Phase-II
15.4 Marketed

16. Dipeptides Clinical Trials Insight By Country, Indication and Phase
16.1 Research
16.2 Preclinical
16.3 Phase-I
16.4 Phase-II
16.5 Phase-III
16.6 Registered
16.7 Marketed

17. Depsipeptides Clinical Trials Insight By Country, Indication and Phase
17.1 Preclinical
17.2 Phase-I
17.3 Phase-II
17.4 Marketed

18. Glycopeptides Clinical Trials Insight By Country, Indication and Phase
18.1 Preclinical
18.2 Phase-I
18.3 Phase-I/II
18.4 Phase-II
18.5 Phase-III
18.6 18.8 Marketed

19. Peptide Vaccines Clinical Trials Insight By Country, Indication and Phase
19.1 Preclinical
19.2 Phase-I/II
19.3 Phase-II
19.4 Phase-III
19.5 Registered
19.6 Marketed

20. Peptide Fragments Clinical Trials Insight By Country, Indication and Phase
20.1 Preclinical
20.2 Phase-I
20.3 Phase-II
20.4 Phase-III
20.5 Preregistration
20.6 Registered
20.7 Marketed

21. Opioid Peptides Clinical Trials Insight By Country, Indication and Phase
21.1 Research
21.2 Preclinical
21.3 Phase-I
21.4 Phase-II
21.5 Preregistration
21.6 Registered
21.7 Marketed

22. Natriuretic Peptides Clinical Trials Insight By Country, Indication and Phase
22.1 Preclinical
22.2 Phase-I
22.3 Phase-II
22.4 Phase-II/III
22.5 Phase-III
22.6 Marketed

23. Neuropeptides Clinical Trials Insight By Country, Indication and Phase
23.1 Research
23.2 Preclinical
23.3 Phase-I
23.4 Phase-I/II
23.5 Phase-II
23.6 Marketed

24. Antimicrobial Cationic Peptides Clinical Trials Insight By Country, Indication and Phase
24.1 Preclinical
24.2 Phase-I
24.3 Phase-III

25. Peptide Hydrolases Clinical Trials Insight By Country, Indication and Phase
25.1 Phase-II

26. Peptide Aptamers
26.1 Research
26.2 Preclinical
26.3 Phase-I
26.4 Phase-II

27. Intercellular Signalling Peptides Clinical Trials Insight By Country, Indication and Phase
27.1 Phase-II

28. Peptide Antibiotics Clinical Trials Insight By Country, Indication and Phase
28.1 Phase-I

29. Peptide Drug Conjugates Clinical Trials Insight By Country, Indication and Phase
29.1 Preclinical

30. Bicyclic Peptides Clinical Trials Insight By Country, Indication and Phase
30.1 Preclinical

31. Multiple Peptides Clinical Trials Insight By Country, Indication and Phase
31.1 Research
31.2 Preclinical
31.3 Phase-I
31.4 Phase-I/II
31.5 Phase-II
31.6 Preregistration
31.7 Registered
31.8 Marketed

32. Competitive Landscape
32.1 AbbVie
32.2 Adocia
32.3 Amgen
32.4 Antlia Bioscience
32.5 AsclepiX Therapeutics
32.6 AstraZeneca
32.7 Bicycle Therapeutics
32.8 Biohaven Labs
32.9 Bristol-Myers Squibb
32.10 Carmot Therapeutics
32.11 Eli Lilly and Company
32.12 Ferring Pharmaceuticals
32.13 GanandLee Pharmaceuticals
32.14 GEROPHARM
32.15 Hanmi Pharmaceutical
32.16 HEC Pharm
32.17 Heidelberg Pharma AG
32.18 ImCyse
32.19 Janux Therapeutics
32.20 Kine Sciences
32.21 Lactocore
32.22 Maxwell Biosciences
32.23 Merck and Co
32.24 Novartis
32.25 Novo Nordisk
32.26 Oryn Therapeutics
32.27 Palatin Technologies
32.28 PeptiDream
32.29 Pfizer
32.30 Priavoid
32.31 Primary Peptides
32.32 Protagonist Therapeutics
32.33 Roche
32.34 Sanofi
32.35 Sapience Therapeutics
32.36 Seagen
32.37 Shaanxi Micot Technology Co
32.38 Stuart Therapeutics
32.39 Takeda
32.40 Zealand Pharma

List of Figures & Table
Figure 1-1: Landmarks in Peptides Drugs Market
Figure 3-1: Pro00013585 Phase II Study - Initiation and Completion Years
Figure 3-2: STUDY0000567 Phase II Study - Initiation and Completion Years
Figure 3-3: NCT05378672 Phase III Study - Initiation and Completion Years
Figure 3-4: ZP4207-21052 Phase III Study - Initiation and Completion Years
Figure 3-5: GLSI-21-01 Phase III Study - Initiation and Completion Years
Figure 3-6: IO102-IO103-013 Phase III Study - Initiation and Completion Years
Figure 3-7: NCT06091748 Phase II Study - Initiation and Completion Years
Figure 3-8: PMC67199 Phase I Study - Initiation and Completion Years
Figure 3-9: ACW-1221958-1 Phase II Study - Initiation and Completion Years
Figure 3-10: NCT05841095 Phase I/II Study - Initiation and Completion Years
Figure 3-11: NCT05340790 Phase I Study - Initiation and Completion Years
Figure 3-12: IR902-007 Phase I Study - Initiation and Completion Years
Figure 3-13: ISEMIS Phase I/II Study - Initiation and Completion Years
Figure 3-14: YN011-301 Phase II/III Study - Initiation and Completion Years
Figure 3-15: SCW0502-1031 Phase III Study - Initiation and Completion Years
Figure 3-16: NCT05202353 Phase I Study - Initiation and Completion Years
Figure 3-17: NCT04305002 Phase II Study - Initiation and Completion Years
Figure 3-18: NCT05189210 Phase II Study - Initiation and Completion Years
Figure 3-19: ALZ-C-001 Phase II Study - Initiation and Completion Years
Figure 3-20: ELViS-FA Phase I/II Study - Initiation and Completion Years
Figure 3-21: NCT05634876 Phase II Study - Initiation and Completion Years
Figure 4-1: CUV104 Phase II Study - Initiation and Completion Years
Figure 4-2: CUV152 Phase II Study - Initiation and Completion Years
Figure 4-3: Peptide-Drug Conjugate Structure
Figure 4-4: NCT04706962 Phase I Study - Initiation and Completion Years
Figure 4-5: MLB-PK-001 Early Phase I Study - Initiation and Completion Year
Figure 4-6: ANGLeD Phase III Study - Initiation and Completion Years
Figure 4-7: CA209-8TX Phase I/II Study - Initiation and Completion Years
Figure 4-8: CLAUDE/EOCRC1-22 Phase II Study - Initiation and Completion Years
Figure 4-9: COVENANT Phase III Study - Initiation and Completion Years
Figure 4-10: EGRABIS1 Phase II Study - Initiation and Completion Years
Figure 4-11: GLIMP Phase II Study - Initiation and Completion Years
Figure 4-12: NCT05530577 Phase II Study - Initiation and Completion Years
Figure 5-1: Global - Peptide Therapeutic Market Size (US$ Billion), 2022 - 2029
Figure 5-2: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2022 - 2029
Figure 5-3: Ongoing Trends in Peptide Drugs Market
Figure 5-4: Future Growth Avenues in Peptide Drugs Market
Figure 6-1: China - Estimated Diabetes Population (Million), 2021 and 2030
Figure 6-2: India - Estimated Diabetes Population (Million), 2021 and 2030
Figure 6-3: ME - Estimated Diabetes Population in Saudi Arabia and UAE (Million), 2021 and 2030
Figure 6-4: Canada - Estimated Diabetes Population (Million), 2021 and 2030
Figure 7-1: Global - Peptides Clinical Trials by Country (Numbers), 2023 Till 2029
Figure 7-2: Global - Peptides Clinical Trials by Indication (Numbers), 2023 Till 2029
Figure 7-3: Global - Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-4: Global - Cyclic Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-5: Global - Peptide Hormones Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-6: Global - Glucagon-Like Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-7: Global - Oligopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-8: Global - Lipopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-9: Global - Dipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-10: Global - Depsipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-11: Global - Glycopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-12: Global - Peptide Vaccines Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-13: Global - Peptide Fragments Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-14: Global - Opioid Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-15: Global - Natriuretic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-16: Global - Neuropeptides Clinical Trials by Phase (Numbers), 2023 till2029
Figure 7-17: Global - Antimicrobial Cationic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-18: Global - Peptide Aptamers Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-19: Global - Peptides Clinical Trials by Priority Status (Numbers), 2023 Till 2029
Figure 7-20: Global - Peptides Clinical Trials by Therapy Class (Numbers), 2023 Till 2029
Figure 8-1: US - Cost per Unit and Supply of Bylvay Oral Capsules (US$), November’2023
Figure 8-2: US - Cost per Unit and Supply of Bylvay Oral Pellets (US$), November’2023
Figure 8-3: EU - Cost per Unit and Supply of Bylvay Oral Capsules and Pellets (Eur/US$), November’2023
Figure 8-4: Global - Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-5: NA - Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-6: Europe - Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-7: ROW - Quarterly Bylvay Sales (US$ Million), 2023
Figure 8-8: Parsabiv - US Patents Expiration Years
Figure 8-9: Parsabiv - Europe Patents Expiration Years
Figure 8-10: Parsabiv - Cost per Unit and Supply (US$), November’2023
Figure 8-11: Global - Annual Parsabiv Sales (US$ Million), 2019-2023
Figure 8-12: US - Annual Parsabiv Sales (US$ Million), 2019-2023
Figure 8-13: ROW - Annual Parsabiv Sales (US$ Million), 2019-2023
Figure 8-14: Global - Quarterly Parsabiv Sales (US$ Million), 2023
Figure 8-15: US - Quarterly Parsabiv Sales (US$ Million), 2023
Figure 8-16: ROW - Quarterly Parsabiv Sales (US$ Million), 2023
Figure 8-17: Global - Quarterly Parsabiv Sales (US$ Million), 2022
Figure 8-18: US - Quarterly Parsabiv Sales (US$ Million), 2022
Figure 8-19: ROW - Quarterly Parsabiv Sales (US$ Million), 2022
Figure 8-20: Bydureon - Year of Approval and Expiry of Patents for Injection
Figure 8-21: Bydureon - Year of Approval and Expiry of Patents for Injection
Figure 8-22: Bydureon BCise - Cost per Unit and Supply (US$), November’2023
Figure 8-23: Global - Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-24: US - Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-25: Europe - Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-26: EM - Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-27: ROW - Annual Bydureon Sales (US$ Million), 2019-2023
Figure 8-28: Global - Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-29: US - Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-30: Europe - Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-31: EM - Quarterly Bydureon Sales (US$ Million), 2023
Figure 8-32: Global - Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-33: US - Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-34: Europe - Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-35: EM - Quarterly Bydureon Sales (US$ Million), 2022
Figure 8-36: Linzess - Cost per Unit and Supply (US$), November’2023
Figure 8-37: Linzess - Dosage by Indication (mcg)
Figure 8-38: Global - Annual Linzess Sales (US$ Million), 2020-2023
Figure 8-39: US - Annual Linzess Sales (US$ Million), 2020-2023
Figure 8-40: ROW - Annual Linzess Sales (US$ Million), 2019-2023
Figure 8-41: Global - Quarterly Linzess Sales (US$ Million), 2023
Figure 8-42: US - Quarterly Linzess Sales (US$ Million), 2023
Figure 8-43: ROW - Quarterly Linzess Sales (US$ Million), 2023
Figure 8-44: Global - Quarterly Linzess Sales (US$ Million), 2022
Figure 8-45: US - Quarterly Linzess Sales (US$ Million), 2022
Figure 8-46: ROW - Quarterly Linzess Sales (US$ Million), 2022
Figure 8-47: Increlex - US and EU Patent Expiry Years
Figure 8-48: Increlex - Cost per Unit and Supply (US$), November’2023
Figure 8-49: Global - Annual Increlex Sales (US$ Million), 2019-2023
Figure 8-50: Global - Quarterly Increlex Sales (US$ Million), 2023
Figure 8-51: Global - Quarterly Increlex Sales (US$ Million), 2022
Figure 8-52 : Terlivaz - Dosing Chart
Figure 8-53: Global - Quarterly Terlivaz Sales (US$ Million), 2023
Figure 8-54: Empaveli - Cost per Unit and Supply (US$), November’2023
Figure 8-55: Empaveli - Cost of Monthly and Yearly Treatment (US$), November’2023
Figure 8-56: Global - Annual Empaveli Sales (US$ Million), 2021-2023
Figure 8-57: US - Annual Empaveli Sales (US$ Million), 2021-2023
Figure 8-58: ROW - Annual Empaveli Sales (US$ Million), 2021-2023
Figure 8-59: Global - Quarterly Increlex Sales (US$ Million), 2023
Figure 8-60: US - Quarterly Empaveli Sales (US$ Million), 2023
Figure 8-61: ROW - Quarterly Empaveli Sales (US$ Million), 2023
Figure 8-62: Global - Quarterly Increlex Sales (US$ Million), 2022
Figure 8-63: US - Annual Empaveli Sales (US$ Million), 2022
Figure 8-64: ROW - Annual Empaveli Sales (US$ Million), 2022
Figure 8-65: Voxzogo - Cost per Unit and Supply (US$), November’2023
Figure 8-66: Global - Annual Voxzogo Sales (US$ Million), 2021-2023
Figure 8-67: Global - Quarterly Voxzogo Sales (US$ Million), 2023
Figure 8-68: Global - Quarterly Voxzogo Sales (US$ Million), 2022
Figure 8-69: Global - Annual Imcivree Sales (US$ Million), 2021-2023
Figure 8-70: Global - Quarterly Imcivree Sales (US$ Million), 2023
Figure 8-71: Global - Quarterly Imcivree Sales (US$ Million), 2022
Figure 8-72: Voxzogo - Cost per Unit and Supply (US$), November’2023
Figure 8-73: Global - Annual Trulicity Sales (US$ Million), 2019-2023
Figure 8-74: Global - Quarterly Trulicity Sales (US$ Million), 2023
Figure 8-75: Global - Quarterly Trulicity Sales (US$ Million), 2022
Figure 8-76: Ozempic - Cost per Unit and Supply (US$), November’2023
Figure 8-77: Ozempic - Initiation and Increment Doses (mg/week)
Figure 8-78: Global - Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-79: NA - Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-80: EMEA - Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-81: China - Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-82: ROW - Annual Ozempic Sales (US$ Million), 2019-2023
Figure 8-83: Global - Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-84: NA - Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-85: EMEA - Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-86: China - Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-87: ROW - Quarterly Ozempic Sales (US$ Million), 2023
Figure 8-88: Global - Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-89: NA - Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-90: EMEA - Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-91: China - Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-92: ROW - Quarterly Ozempic Sales (US$ Million), 2022
Figure 8-93: Wegovy - Cost per Unit and Supply of 0.25mg, 0.5mg and 1mg Solutions (US$), November’2023
Figure 8-94: Wegovy - Cost per Unit and Supply of 1.7mg, and 2.4mg Solutions (US$), November’2023
Figure 8-95: Global - Annual Wegovy Sales (US$ Million), 2021-2023
Figure 8-96: NA - Annual Wegovy Sales (US$ Million), 2021-2023
Figure 8-97: EMEA - Annual Wegovy Sales (US$ Million), 2021-2023
Figure 8-98: Global - Quarterly Wegovy Sales (US$ Million), 2023
Figure 8-99: NA - Quarterly Wegovy Sales (US$ Million), 2023
Figure 8-100: EMEA - Quarterly Wegovy Sales (US$ Million), 2023
Figure 8-101: Global - Quarterly Wegovy Sales (US$ Million), 2022
Figure 8-102: NA - Quarterly Wegovy Sales (US$ Million), 2022
Figure 8-103: EMEA - Quarterly Wegovy Sales (US$ Million), 2022
Figure 8-104: Tresiba - Cost per Unit and Supply of 100 units/mL Solution (US$), November’2023
Figure 8-105: Tresiba - Cost per Unit and Supply of 200 units/mL Solution (US$), November’2023
Figure 8-106: Insulin degludec - Cost per Unit and Supply of 100 units/mL Solution (US$), November’2023
Figure 8-107: Global - Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-108: NA - Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-109: EMEA - Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-110: China - Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-111: ROW - Annual Tresiba Sales (US$ Million), 2019-2023
Figure 8-112: Global - Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-113: NA - Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-114: EMEA - Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-115: China - Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-116: ROW - Quarterly Tresiba Sales (US$ Million), 2023
Figure 8-117: Global - Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-118: NA - Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-119: EMEA - Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-120: China - Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-121: ROW - Quarterly Tresiba Sales (US$ Million), 2022
Figure 8-122: Rybelsus - Cost per Unit and Supply (US$), November’2023
Figure 8-123: Global - Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-124: NA - Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-125: EMEA - Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-126: China - Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-127: ROW - Annual Rybelsus Sales (US$ Million), 2019-2023
Figure 8-128: Global - Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-129: NA - Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-130: EMEA - Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-131: China - Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-132: ROW - Quarterly Rybelsus Sales (US$ Million), 2023
Figure 8-133: Global - Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-134: NA - Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-135: EMEA - Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-136: China - Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-137: ROW - Quarterly Rybelsus Sales (US$ Million), 2022
Figure 8-138: Xultophy - Cost per Unit and Supply (US$), November’2023
Figure 8-139: Global - Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-140: NA - Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-141: EMEA - Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-142: China - Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-143: ROW - Annual Xultophy Sales (US$ Million), 2019-2023
Figure 8-144: Global - Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-145: NA - Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-146: EMEA - Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-147: China - Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-148: ROW - Quarterly Xultophy Sales (US$ Million), 2023
Figure 8-149: Global - Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-150: NA - Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-151: EMEA - Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-152: China - Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-153: ROW - Quarterly Xultophy Sales (US$ Million), 2022
Figure 8-154: Victoza - Cost per Unit and Supply (US$), November’2023
Figure 8-155: Global - Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-156: North America - Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-157: EMEA - Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-158: China - Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-159: ROW - Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-160: Global - Quarterly Victoza Sales (US$ Million), 2023
Figure 8-161: North America - Quarterly Victoza Sales (US$ Million), 2023
Figure 8-162: EMEA - Quarterly Victoza Sales (US$ Million), 2023
Figure 8-163: China - Quarterly Victoza Sales (US$ Million), 2023
Figure 8-164: ROW - Quarterly Victoza Sales (US$ Million), 2023
Figure 8-165: Global - Quarterly Victoza Sales (US$ Million), 2022
Figure 8-166: North America - Quarterly Victoza Sales (US$ Million), 2022
Figure 8-167: EMEA - Quarterly Victoza Sales (US$ Million), 2022
Figure 8-168: China - Quarterly Victoza Sales (US$ Million), 2022
Figure 8-169: ROW - Quarterly Victoza Sales (US$ Million), 2022
Figure 8-170: Global - Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-171: EMEA - Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-172: China - Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-173: ROW - Annual Victoza Sales (US$ Million), 2019-2023
Figure 8-174: Global - Quarterly Victoza Sales (US$ Million), 2023
Figure 8-175: EMEA - Quarterly Victoza Sales (US$ Million), 2023
Figure 8-176: China - Quarterly Victoza Sales (US$ Million), 2023
Figure 8-177: ROW - Quarterly Victoza Sales (US$ Million), 2023
Figure 8-178: Global - Quarterly Victoza Sales (US$ Million), 2022
Figure 8-179: EMEA - Quarterly Victoza Sales (US$ Million), 2022
Figure 8-180: China - Quarterly Victoza Sales (US$ Million), 2022
Figure 8-181: ROW - Quarterly Victoza Sales (US$ Million), 2022
Figure 8-182: Fiasp - Cost per Unit and Supply (US$), November’2023
Figure 8-183: Global - Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-184: NA - Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-185: EMEA - Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-186: ROW - Annual Fiasp Sales (US$ Million), 2019-2023
Figure 8-187: Global - Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-188: NA - Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-189: EMEA - Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-190: ROW - Quarterly Fiasp Sales (US$ Million), 2023
Figure 8-191: Global - Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-192: NA - Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-193: EMEA - Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-194: ROW - Quarterly Fiasp Sales (US$ Million), 2022
Figure 8-195: Lantus - Cost per Unit and Supply (US$), November’2023
Figure 8-196: Insulin Glargine and Insulin Glargine-yfgn - Cost per Unit and Supply (US$), November’2023
Figure 8-197: Global - Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-198: US - Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-199: Europe - Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-200: ROW - Annual Lantus Sales (US$ Million), 2019-2023
Figure 8-201: Global - Quarterly Lantus Sales (US$ Million), 2023
Figure 8-202: US - Quarterly Lantus Sales (US$ Million), 2023
Figure 8-203: Europe - Quarterly Lantus Sales (US$ Million), 2023
Figure 8-204: ROW - Quarterly Lantus Sales (US$ Million), 2023
Figure 8-205: Global - Quarterly Lantus Sales (US$ Million), 2022
Figure 8-206: US - Quarterly Lantus Sales (US$ Million), 2022
Figure 8-207: Europe - Quarterly Lantus Sales (US$ Million), 2022
Figure 8-208: ROW - Quarterly Lantus Sales (US$ Million), 2022
Figure 8-209: Toujeo - US Patent Acceptance and Expiration Years
Figure 8-210: Toujeo - Cost per Unit and Supply (US$), November’2023
Figure 8-211: Global - Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-212: US - Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-213: Europe - Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-214: ROW - Annual Toujeo Sales (US$ Million), 2019-2023
Figure 8-215: Global - Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-216: US - Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-217: Europe - Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-218: ROW - Quarterly Toujeo Sales (US$ Million), 2023
Figure 8-219: Global - Quarterly Toujeo Sales (US$ Million), 2022
Figure 8-220: US - Quarterly Toujeo Sales (US$ Million), 2022
Figure 8-221: Europe - Quarterly Toujeo Sales (US$ Million), 2022
Figure 8-222: ROW - Quarterly Toujeo Sales (US$ Million), 2022
Figure 9-1: Biodrug Design Accelerator - Technical Benefits
Figure 9-2: Biodrug Design Accelerator - Technical Benefits
Figure 9-3: IO Biotech - T-win Technology
Figure 9-4: Numatech - Numaferm Platform
Figure 9-5: Nuritas - Scientific Achievements of Magnifier Nandpi;andPhi; Bioactive Peptide Discovery Platform
Figure 9-6: Nuritas - The Magnifier Nandpi;andPhi; Bioactive Peptide Discovery Process
Figure 9-7: Nuritas - The Magnifier Nandpi;andPhi; Bioactive Peptide Results
Figure 9-8: GenScript - PepPower Technology
Figure 9-9: PeptiDream - PDPS Outline
Figure 9-10: PeptiDream - PDPS Outline
Figure 9-11: PeptiDream - PDPS Features
Figure 9-12: Benefits of DRPs as Drug Molecule Scaffold
Figure 9-13: Veneno Technologies - Veneno Suite Components
Figure 9-14: Veneno Technologies - Veneno Suite Process
Figure 9-15: Peptron - SmartDepotandtrade; Features
Figure 9-16: Peptron - SmartDepotandtrade; Manufacturing Scheme
Figure 9-17: Bicycle Therapeutics - Bicycles Key Properties
Figure 9-18: Bicycle Therapeutics - Bicycles Key Properties
Figure 9-19: pHion Therapeutics - RALA Nanoparticles Advantages
Figure 9-20: pHion Therapeutics - RALA Nanoparticles BENEFITS
Figure 9-21: Orbit Discovery - Orbit Peptide Display Engine
Figure 9-22: Benefits of Imotopes over Current Therapies
Figure 9-23: Peptilogics - Peptide Development Process
Figure 9-24: Peptilogics - Nautilus Features
Figure 9-25: Pepticom - Swarm Intelligence 2.0 AI platform
Figure 9-26: Cybrexa - alphalex Selective Tumor Cell Targeting

List of Tables
Table 1- 1: Landmarks in Peptides Drugs Market
Table 6-1: US - Recent FDA Designations for Peptide Drug Candidates
Table 8-1: Bylvay - Recommended Dosage for 40 mcg/kg/day
Table 8-2: Parsabiv - Recommended Schedule for Monitoring Corrected Serum Calcium and Parathyroid Hormone Levels during Treatment
Table 8-3: Voxzogo - Recommended Daily Dosage and Injection Volume
Table 8-4: Wegovy - Recommended Dosage Regimen for Adults
Table 8-5: Wegovy - Recommended Dosage Regimen for Pediatric Patients Aged 12 Years and Older
Table 9-1: GenScript - PepPowerandtrade; Platform Advantages